Exchange: NASDAQ·Updated 06:46 PM EDT
KNSA logo

KNSAKiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

$64.43
$2.84
(4.65%)
Today
Closed $63.95
$0.4836
(0.76%)
After Hours
EarningsJul 28
Mkt Cap$4.7B
Vol712,521.00
News
all
press releases
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
Zacks
News Placeholder
More News
News Placeholder
UnitedHealth Tops Q2 Earnings on Cost Control, Raises '26 Outlook
UNH beats Q2 earnings estimates on lower medical costs and stronger Optum Insight, then raises its 2026 EPS and cash flow outlook.
Zacks
News Placeholder
ATAI Stock Soars on Reports of Potential Acquisition by Eli Lilly
AtaiBeckley stock surges after a Bloomberg report said Eli Lilly is in talks for a potential acquisition of the company, as investors await details of the deal.
Zacks
News Placeholder
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
Zacks
News Placeholder
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
Let's take a look at four stocks, FLXS, ARKO, KNSA and BSET, with impressive net profit margins for a robust portfolio.
Zacks
News Placeholder
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.
Zacks
News Placeholder
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Zacks
News Placeholder
Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue?
Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
News Placeholder
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks
News Placeholder
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
<
1
2
...
>

Advertisement|Remove ads.